Filing search / Olema Pharmaceuticals, Inc. / "Safety"

8-K

EX-99.1

OLMA Olema Pharmaceuticals, Inc.

27 Sep 24

Regulation FD Disclosure

7:00am

and potential beneficial characteristics, profile, safety, tolerability, efficacy and therapeutic effects of palazestrant as a monotherapy … , the best-in-class potential for OP-3136, the potential beneficial characteristics, profile, safety, efficacy, tolerability, and therapeutic effects

8-K

EX-99.1

OLMA Olema Pharmaceuticals, Inc.

6 Aug 24

Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update

4:10pm

with no new safety signals or enhancement of toxicity. The preliminary efficacy data is highly encouraging and we look forward to updating with more … , Germany. Results showed palazestrant in combination with ribociclib was well tolerated with no new safety signals or enhancement of toxicity

8-K

EX-99.2

OLMA Olema Pharmaceuticals, Inc.

15 May 24

Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress

7:06am

with ribociclib, the potential beneficial characteristics, profile, safety, tolerability, efficacy and therapeutic effects of palazestrant as a monotherapy … approved for marketing by the U.S. Food and Drug Administration. No representation is made as to the safety or effectiveness of these product candidates

8-K

OLMA Olema Pharmaceuticals, Inc.

15 May 24

Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress

7:06am

with the full and approved dose of 600 mg of ribociclib daily was well tolerated, with no new safety signals or enhancement of toxicity and an overall … safety profile consistent with the established safety profile of ribociclib plus an endocrine therapy. Palazestrant did not affect ribociclib drug

8-K

EX-99.1

3mu4e6zb36w72obbzi5

15 May 24

Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress

7:06am

8-K

EX-99.1

ce37 6paj3vddb

8 May 24

Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

4:06pm

8-K

EX-99.1

flxk4bjf8dpir7prf

11 Mar 24

Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

4:05pm

424B3

qvvrp4mgexldk2zqmc

12 Feb 24

Prospectus supplement

5:16pm

8-K

EX-99.1

8304s0m96g2 1ro61zxm

8 Jan 24

Olema Oncology JP Morgan Conference January 2024

9:07am

8-K

EX-1.1

3hlakd

5 Jan 24

Entry into a Material Definitive Agreement

5:26pm

424B5

k9iep

5 Jan 24

Prospectus supplement for primary offering

5:25pm

8-K

EX-99.1

asbnjfdy9zh6s6av

6 Dec 23

Regulation FD Disclosure

7:48am

8-K

68t1i8vd2z b1hlbs

5 Dec 23

Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies

5:15pm

8-K

EX-99.1

r5tiyyurfhvb3m

5 Dec 23

Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies

5:15pm